Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Short Interest Update

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) was the target of a large decrease in short interest in March. As of March 13th, there was short interest totaling 40,790 shares, a decrease of 25.7% from the February 26th total of 54,874 shares. Based on an average daily volume of 51,489 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.8% of the company’s stock are short sold.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Chemomab Therapeutics in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $25.00.

Institutional Trading of Chemomab Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in CMMB. ADAR1 Capital Management LLC bought a new stake in Chemomab Therapeutics in the 4th quarter valued at $132,000. Kestra Private Wealth Services LLC bought a new position in Chemomab Therapeutics during the fourth quarter worth $85,000. Finally, XTX Topco Ltd bought a new position in Chemomab Therapeutics during the fourth quarter worth $31,000. 46.05% of the stock is currently owned by institutional investors and hedge funds.

Chemomab Therapeutics Trading Down 5.8%

Shares of Chemomab Therapeutics stock traded down $0.09 during trading on Friday, reaching $1.46. The stock had a trading volume of 41,042 shares, compared to its average volume of 66,213. The company has a market capitalization of $8.99 million, a price-to-earnings ratio of -0.57 and a beta of 0.41. The stock has a fifty day moving average price of $1.69 and a two-hundred day moving average price of $2.25. Chemomab Therapeutics has a 52 week low of $1.35 and a 52 week high of $5.88.

Chemomab Therapeutics (NASDAQ:CMMB) last posted its quarterly earnings data on Thursday, March 19th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). On average, equities analysts forecast that Chemomab Therapeutics will post -1 EPS for the current fiscal year.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.